COMMUNIQUÉS West-GlobeNewswire

Verrica Pharmaceuticals Announces Participation in the Cowen and Company 39th Annual Healthcare Conference
27/02/2019
WEST CHESTER, Pa., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical [...]
Antares Pharma to Present at the Raymond James & Associates 40th Annual Institutional Investors Conference
27/02/2019
EWING, N.J., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James & Associates 40 th [...]
Delight Announces Availability of its Oasis-RC New Wirelessly Charged Personal Sound Amplification Product (PSAP)
27/02/2019
SEOUL, South Korea, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Delight, a company committed to making hearing aid solutions more accessible for consumers, today announced that its new wirelessly charged personal sound [...]
OraSure Technologies to Present at the Raymond James 40th Annual Institutional Investors Conference
27/02/2019
BETHLEHEM, Pa., Feb. 27, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, [...]
Amarin Reports Record Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Operations
27/02/2019
Record Revenue of $229.2 Million and $ 77.3 Million for Full Year and Fourth Quarter 2018 REDUCE-IT™ sNDA Submission Remains on Schedule to be Filed Before the End of Q1 2019 Management to Host Conference Call at 7:30 a [...]
Nexstim Plc Postpones its 2018 Full Year Results Release to Monday 4 March 2019
27/02/2019
Company announcement, Helsinki, 27.02.2019 at 09.00 Finnish time (EET) Nexstim Plc Postpones its 2018 Full Year Results Release to Monday 4 March 2019 Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), the [...]
111, Inc. Announces the Appointment of a New Chief Financial Officer
27/02/2019
SHANGHAI, China, Feb. 27, 2019 (GLOBE NEWSWIRE) -- 111, Inc. (Nasdaq: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform, today announced that Mr. Yang Chen has been appointed as [...]
Esperite N.V. (ESP) with The Cell Factory has confirmed a long-term effect of extracellular vesicle drug candidate CF-MEV-132 for the treatment of Bronchopulmonary Dysplasia.
27/02/2019
CF-MEV-132 drug candidate belongs to the CF-MEV family of anti-inflammatory EV drugs produced by The Cell Factory Amsterdam, The Netherlands – 27 February 2019 The Cell Factory and the University of Padova, Italy have [...]
Annual Report 2018: GN delivers on guidance with 13% organic growth and EBITA margin increase – 18% organic growth in Q4 2018
27/02/2019
Financial highlights 2018 GN delivered DKK 10.6 billion revenue with organic growth at 13% EBITA reached DKK 2.0 billion, with an EBITA margin increase of 0.2 percentage points, based on strong execution in GN Hearing [...]
ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019
27/02/2019
Geneva, Switzerland and Boston, MA –February 27, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for [...]
Acacia Pharma Group plc Results For The Year Ended 31 December 2018
27/02/2019
Cambridge, UK and Indianapolis, US – 27 February 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and [...]
The rolling submission to FDA for darolutamide in the U.S. completed
27/02/2019
Orion Corporation Press Release Communications 27 February 2019 at 07:00 a.m. EET The rolling submission to FDA for darolutamide in the U.S. completed Orion Corporation and Bayer today announced the completion of the [...]
111 to Announce Fourth Quarter and Fiscal Year 2018 Unaudited Financial Results on March 7, 2019
27/02/2019
SHANGHAI, China, Feb. 26, 2019 (GLOBE NEWSWIRE) -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform in China, today announced that it will report its unaudited [...]
Wildflower Debuts to Celebrities at the Oscars
27/02/2019
VANCOUVER, British Columbia, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Wildflower Brands Inc. (CSE: SUN , OTC: WLDFF ) (the “Company”) is thrilled to announce that Wildflower products were selected for inclusion in the 2019 [...]
Ultragenyx Announces Pricing of Public Offering of Common Stock
27/02/2019
NOVATO, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, [...]
Adamis Provides Regulatory Update on Sublingual Tadalafil
27/02/2019
SAN DIEGO, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) [...]
ASLAN Pharmaceuticals to Partner With BioGenetics on Commercialisation of Varlitinib in South Korea
26/02/2019
SINGAPORE, Feb. 27, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets, and BioGenetics [...]
Precision Therapeutics Inc. Announces Proposed Public Offering of Securities
26/02/2019
MINNEAPOLIS, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced a proposed public offering of its common stock and warrants to purchase common [...]
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
26/02/2019
Phase 3 Geographic Atrophy Program Expected to Restart By or In Q2 2019 Phase 3 Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria Expected to be Fully Enrolled by End of Q2 2019 Cash Position of $176.3 [...]

Pages